117 related articles for article (PubMed ID: 18657401)
1. Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents.
Brocco M; Dekeyne A; Mannoury la Cour C; Touzard M; Girardon S; Veiga S; de Nanteuil G; deJong TR; Olivier B; Millan MJ
Eur Neuropsychopharmacol; 2008 Oct; 18(10):729-50. PubMed ID: 18657401
[TBL] [Abstract][Full Text] [Related]
2. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
[TBL] [Abstract][Full Text] [Related]
3. Investigating the effect of bilateral amygdala lesions on fear conditioning and social interaction in the male Mongolian gerbil.
Woolley ML; Haman M; Higgins GA; Ballard TM
Brain Res; 2006 Mar; 1078(1):151-8. PubMed ID: 16494851
[TBL] [Abstract][Full Text] [Related]
4. S41744, a dual neurokinin (NK)1 receptor antagonist and serotonin (5-HT) reuptake inhibitor with potential antidepressant properties: a comparison to aprepitant (MK869) and paroxetine.
Millan MJ; Dekeyne A; Gobert A; Mannoury la Cour C; Brocco M; Rivet JM; Di Cara B; Lejeune F; Cremers TI; Flik G; de Jong TR; Olivier B; de Nanteuil G
Eur Neuropsychopharmacol; 2010 Sep; 20(9):599-621. PubMed ID: 20483567
[TBL] [Abstract][Full Text] [Related]
5. The tachykinin NK3 receptor agonist senktide induces locomotor activity in male Mongolian gerbils.
Nordquist RE; Durkin S; Jacquet A; Spooren W
Eur J Pharmacol; 2008 Dec; 600(1-3):87-92. PubMed ID: 18930726
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonist.
Megens AA; Ashton D; Vermeire JC; Vermote PC; Hens KA; Hillen LC; Fransen JF; Mahieu M; Heylen L; Leysen JE; Jurzak MR; Janssens F
J Pharmacol Exp Ther; 2002 Aug; 302(2):696-709. PubMed ID: 12130734
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.
Cirillo R; Astolfi M; Conte B; Lopez G; Parlani M; Sacco G; Terracciano R; Fincham CI; Sisto A; Evangelista S; Maggi CA; Manzini S
Neuropeptides; 2001; 35(3-4):137-47. PubMed ID: 11884203
[TBL] [Abstract][Full Text] [Related]
8. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole.
Millan MJ; Brocco M; Papp M; Serres F; La Rochelle CD; Sharp T; Peglion JL; Dekeyne A
J Pharmacol Exp Ther; 2004 Jun; 309(3):936-50. PubMed ID: 14978196
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo pharmacological characterization of the novel NK₁ receptor selective antagonist Netupitant.
Rizzi A; Campi B; Camarda V; Molinari S; Cantoreggi S; Regoli D; Pietra C; Calo' G
Peptides; 2012 Sep; 37(1):86-97. PubMed ID: 22732666
[TBL] [Abstract][Full Text] [Related]
10. LY303870, a centrally active neurokinin-1 antagonist with a long duration of action.
Iyengar S; Hipskind PA; Gehlert DR; Schober D; Lobb KL; Nixon JA; Helton DR; Kallman MJ; Boucher S; Couture R; Li DL; Simmons RM
J Pharmacol Exp Ther; 1997 Feb; 280(2):774-85. PubMed ID: 9023291
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists.
Smith BJ; Doran AC; McLean S; Tingley FD; O'Neill BT; Kajiji SM
J Pharmacol Exp Ther; 2001 Sep; 298(3):1252-9. PubMed ID: 11504828
[TBL] [Abstract][Full Text] [Related]
12. The NK1 receptor antagonist NKP608 lacks anxiolytic-like activity in Swiss-Webster mice exposed to the elevated plus-maze.
Rodgers RJ; Gentsch C; Hoyer D; Bryant E; Green AJ; Kolokotroni KZ; Martin JL
Behav Brain Res; 2004 Sep; 154(1):183-92. PubMed ID: 15302124
[TBL] [Abstract][Full Text] [Related]
13. Stereospecific blockade of marble-burying behaviour in mice by selective, non-peptidergic neurokinin1 (NK1) receptor antagonists.
Millan MJ; Girardon S; Mullot J; Brocco M; Dekeyne A
Neuropharmacology; 2002 Apr; 42(5):677-84. PubMed ID: 11985826
[TBL] [Abstract][Full Text] [Related]
14. SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]-4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin 1 receptor: II. Neurochemical and behavioral characterization.
Steinberg R; Alonso R; Rouquier L; Desvignes C; Michaud JC; Cudennec A; Jung M; Simiand J; Griebel G; Emonds-Alt X; Le Fur G; Soubrié P
J Pharmacol Exp Ther; 2002 Dec; 303(3):1180-8. PubMed ID: 12438542
[TBL] [Abstract][Full Text] [Related]
15. Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
Hale JJ; Mills SG; MacCoss M; Finke PE; Cascieri MA; Sadowski S; Ber E; Chicchi GG; Kurtz M; Metzger J; Eiermann G; Tsou NN; Tattersall FD; Rupniak NM; Williams AR; Rycroft W; Hargreaves R; MacIntyre DE
J Med Chem; 1998 Nov; 41(23):4607-14. PubMed ID: 9804700
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological blockade or genetic deletion of substance P (NK(1)) receptors attenuates neonatal vocalisation in guinea-pigs and mice.
Rupniak NM; Carlson EC; Harrison T; Oates B; Seward E; Owen S; de Felipe C; Hunt S; Wheeldon A
Neuropharmacology; 2000 Jun; 39(8):1413-21. PubMed ID: 10818257
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and pharmacological characterization of constrained analogues of Vestipitant as in vitro potent and orally active NK(1) receptor antagonists.
Sabbatini FM; Di Fabio R; Griffante C; Pentassuglia G; Zonzini L; Melotto S; Alvaro G; Capelli AM; Pippo L; Perdona' E; St Denis Y; Costa S; Corsi M
Bioorg Med Chem Lett; 2010 Jan; 20(2):623-7. PubMed ID: 19963378
[TBL] [Abstract][Full Text] [Related]
18. NKP608: a selective NK-1 receptor antagonist with anxiolytic-like effects in the social interaction and social exploration test in rats.
Vassout A; Veenstra S; Hauser K; Ofner S; Brugger F; Schilling W; Gentsch C
Regul Pept; 2000 Dec; 96(1-2):7-16. PubMed ID: 11102646
[TBL] [Abstract][Full Text] [Related]
19. The neurokinin-1 antagonist activity of maropitant, an antiemetic drug for dogs, in a gerbil model.
de la Puente-Redondo V; Tingley FD; Schneider RP; Hickman MA
J Vet Pharmacol Ther; 2007 Aug; 30(4):281-7. PubMed ID: 17610400
[TBL] [Abstract][Full Text] [Related]
20. Reinstatement of episodic-like memory in rats by neurokinin-1 receptor antagonism.
Kart-Teke E; Dere E; Brandão ML; Huston JP; De Souza Silva MA
Neurobiol Learn Mem; 2007 Mar; 87(3):324-31. PubMed ID: 17079168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]